Kornimate/medical-research-clean huggingface dataset:
adoptive cell therapy following non-myeloablate chemotherapy in metastatic melanoma patients

Conditions: Metastatic Melanoma

Summary: metastatic melanoma is an aggressive and highly malignant cancer. the five-year survival rate of patients with metastatic disease is less than 5% with a median survival of only 6-10 months. drugs like dacarbazin (dtic) as a single agent or in combination with other chemotherapy agents, have a response rate of 15-30%, but the duration of response is usually short, with no impact on survival. interleukin-2 (il-2) based immunotherapy has shown more promising results. this form of therapy has a similar response rate with some patients achieving a durable complete response. recently the national institute of health (nih) reported that by using lympho-depleting chemotherapy, followed by an adoptive transfer of large numbers of anti-tumor specific tumor-infiltrating lymphocytes (til), an objective regression was achieved in 51% of patients with metastatic melanoma. objectives: to introduce the til technology to advanced metastatic melanoma patients in israel.


Eligibility criteria:
inclusion criteria: * metastatic melanoma patients failing to prior chemo and immunotherapy with good performance status. exclusion criteria: * brain mets

Keywords: melanoma metastatic melanoma adoptive immunotherapy il-2
more effective violence risk management - edasa+app fi

Conditions: Violence

Summary: the main goal of this study is to evaluate if the finnish version of edasa+app (electronic dynamic appraisal of situational aggression + aggression prevention protocol), a clinical decision support system (cdss), has an impact on reducing workplace violence, use of coercive measures and increasing nurses' job satisfaction in adult psychiatric inpatient care.

the study includes three phases: 1) exploring attitudes of nurses and nurse managers towards validated tools, violence risk assessment and management, 2) a pre-implementation including a co-design process of the edasa+app to ensure optimal integration and adaptation to local context and integration into the local epic based ehr system together with relevant stakeholders (health care staff and expert-by-experience), and 3) a quasi-experimental implementation study to evaluate the impact of the intervention (edasa+app fi).

Eligibility criteria:
inclusion criteria: * adult psychiatric wards exclusion criteria: * psychiatric wards specialized only for the care of people with intellectual disabilities, wards providing care for both adults and underaged patients (eating disorder units)

Keywords: violence risk assessment dasa dynamic appraisal of situational aggression mental health nursing epic electronic health records violence risk management inpatient psychiatric care coercive measures clinical decision support system cdss co-design nurse-patient collaboration
a study to evaluate the pharmacokinetics (drug levels and metabolism), safety, and tolerability of bms-986259 in participants with various levels of kidney function

Conditions: Renal Failure

Summary: a study to evaluate the drug effect, safety, and tolerability of bms-986259 in participants with different levels of kidney function

recruitment temporarily on hold due to covid-19

Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * participant must have renal impairment, as defined by egfr at screening using the chronic kidney disease epidemiology (ckd-epi) equation * no change in medications to control chronic kidney disease (ckd) for at least 2 weeks prior to dosing, and if possible, during confinement in the clinical research unit (cru), except those cleared by the investigator and medical monitor. * participants with normal renal function at screening, based upon the opinion of the investigator's medical evaluation. * medically well-controlled disorders (eg, stable chronic asthma, allergy) are permitted if the treatment for the disease does not interfere with the study. * women and men must use highly effective methods of contraception for the duration of treatment exclusion criteria: * history of any significant drug allergy or drug-related serious adverse events (sae) (such as anaphylaxis or hepatotoxicity) * positive results for drugs abuse in urine/saliva * participants undergoing any method of dialysis (eg, hemodialysis, peritoneal dialysis) within the last 3 months or with anticipated need for dialysis during the study * evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ecg, or clinical laboratory assessments beyond what is consistent with the target population * known previous exposure to bms-986259 other inclusion/exclusion criteria apply
efficiency of use of baracetinib in treatment of lupus nephritis

Conditions: Lupus Nephritis

Summary: patients with systemic lupus erythematosus have substantial unmet medical need. baricitinib is an oral selective janus kinase (jak)1 and jak2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus and had a diagnosis of systemic lupus erythematosus, and had active renal disease as defined by systemic lupus erythematosus disease activity index-2000 (sledai-2k). efficacy and safety analyses included all patients who received at least one dose of study drug.

patients with systemic lupus erythematosus have substantial unmet medical need. baricitinib is an oral selective janus kinase (jak)1 and jak2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus and had a diagnosis of systemic lupus erythematosus, and had active renal disease as defined by systemic lupus erythematosus disease activity index-2000 (sledai-2k). efficacy and safety analyses included all patients who received at least one dose of study drug. the baricitinib 4 mg dose suggestive to significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricitinib. this study provides the idea for future trials of jak1/2 inhibition with baricitinib as a new potential oral therapy for

Eligibility criteria:
inclusion criteria: * lupus nephritis exclusion criteria: * cardiac disease thrombosis
ivig vs scig in cidp

Conditions: CIDP; Immunoglobulin Deficiency; Chronic Inflammatory Demyelinating Polyneuropathy

Summary: current dosing practices for immunoglobulin g (igg) may be inadequate in extreme body weight. the current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin g in patients.

current dosing practices for immunoglobulin g (igg) may be inadequate in extreme body weight. total (tbw), ideal (ibw), and adjusted (adjbw) body weight-based dosing strategies are suggested, but these recommendations are based on expert opinion rather than high quality evidence. the adoption of a specific strategy is highly variable depending on the clinician and/or institutional setting. recently, payors have also adopted strategies to reduce igg therapy costs of by capping doses. these recommendations are often based on the presumption that igg distribution is limited to the vascular space. while this assertion is logical, it does not account for changes adipose tissue may confer on target sites, nor does it account for the potential for adipose tissue to function serve as a metabolic sink or a source of inflammatory mediators. the later would be especially important in patients receiving scig. several observational studies have evaluated igg dosing in obese patients and have been the source of support for dosing strategies. many of these studies were not representative of specific populations, contained a wide variety of patients with different igg indications, and had inadequate serum sampling. more recently, the phase iii randomized controlled path trial did not find a correlation with serum igg concentrations and clinical endpoints. however, it is important to note that the study was not designed to evaluate pharmacokinetic and pharmacodynamic endpoints. there is also considerable interpatient variation in response; therefore, identification of patient characteristics that predict response or igg change from baseline will be a useful tool to improve patient responses. our study will evaluate the influence of body composition and other patient characteristics may have on igg exposure when given intravenously or subcutaneously.

Eligibility criteria:
inclusion criteria: * patients aged \>18 years with a current diagnosis of cidp (based on european federation of neurological sciences / peripheral nerve society cidp diagnostic criteria). * 1:1 conversion of ivig to scig (weekly dose conversion) must fall within 0.2-to-0.4 mg/kg dose for scig. exclusion criteria: * patients receiving ivig for indications other than cidp will be excluded. * patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (crcl \< 50 ml/min) will be excluded * active malignancies * diabetes * myasthenia gravis * immunodeficiency * autoimmune disease

Keywords: immunoglobulin pharmacokinetics obesity
dynaloc for treatment of femoral neck fractures

Conditions: Femoral Neck Fracture

Summary: a prospective, randomized study comparing the effectiveness of a new system, dynaloc compared with three cancellous screws, for osteosynthesis of femoral neck fractures


Eligibility criteria:
inclusion criteria: * adult men or women (see age specifications below) with subcapital femoral neck fractures (stable or unstable) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging (mri). * patients between 50 and 69 years of age with any garden type femoral neck fracture * patients older than 70 years of age with femoral neck fractures garden type i and ii * patients older than 70 years of age with a femoral neck fracture garden types iii and iv and contraindication to hemiarthroplasty. * operative treatment within 4 days (i.e., 72 hours) of presenting to the emergency room. * patient was ambulatory prior to fracture, though they may have used an aid such as a cane or a walker. * anticipated medical optimalization of the patient for operative fixation of the hip. * provision of informed consent by patient or proxy. * low energy fracture (defined as a fall from standing height). * no other major trauma. exclusion criteria: * associated major injuries of the lower extremity (i.e., ipsilateral or contralateral fractures of the foot, ankle, tibia, fibula, knee, or femur; dislocations of the ankle, knee, or hip; or femoral head defects or fracture). * retained hardware around the affected hip. * abnormal opposite hip making end-point evaluation impossible * infection around the hip (i.e., soft tissue or bone). * patients with disorders of bone metabolism other than osteoporosis (i.e., paget's disease, renal osteodystrophy). * moderate or severe cognitively impaired patients (i.e., six item screener with three or more errors). * patients with parkinson's disease (or dementia or other neurological deficit) severe enough to increase the likelihood of falling or severe enough to compromise rehabilitation. * likely problems, in the judgment of the investigators, with maintaining follow-up. we will, for example, exclude patients with no fixed address, those who report a plan to move out of town in the next year, or intellectually challenged patients without adequate family support.
trial of enteral glutamine on clinical outcomes in critically ill patients

Conditions: Critical Illness; Enteral Nutrition; Multiple Organ Failure; Infection Complication; Inflammation

Summary: glutamine supplementation has beneficial effects on morbidity and mortality in critically ill patients, possibly in part through an attenuation of the proinflammatory cytokine response and a immune function. in this trial intensive care unit patients with enteral feeding will receive either enteral glutamine or maltodextrin as placebo for 28 days.

a randomized, double blind, controlled trial will be conducted in general intensive care unit (icu) in tehran, iran. after a full review of the inclusion and exclusion criteria and explanation of the risks and benefits of the study, written consent form will be completed. the participants are 200 eligible hospitalized patients with enteral feeding in icu, aged ≥ 18 years. intervention patients will be received 0.3 g/kg/day of glutamine along with enteral formula for 28 days and control patients will be received maltodextrin along with enteral formula for 28 days. patients will be evaluated for occurrence of new infection, organ failure, duration of stay in icu, 28 days and 6 months mortality and inflammatory and immune markers.

Eligibility criteria:
inclusion criteria: * adult patients (\>18 years old) admitted to icu * start of study intervention within 48 hours after icu admission * expected to require enteral nutrition for at least 72 hours aiming for full enteral nutrition and receive at least 80 percent of enteral formula during the first 48 hour * written informed consent of patient or written informed consent of legal representative exclusion criteria: * enrollment in a related icu interventional study * requiring other specific enteral nutrition for medical reason * death or discharge before 5th day * having any contra-indication to receive enteral nutrition * pregnant patients or lactating with the intent to breastfeed * requiring other specific enteral nutrition for medical reason * bmi \ 40.0 kg/m2 * have life expectancy of \<6 mo * patients who are moribond * liver cirrhosis- child's class c liver disease * have seizure disorder requiring anticonvulsant * history of allergy or intolerance to the study product components * receiving glutamine during two weeks before start study product * have other reasons

Keywords: glutamin enteral nutrition intensive care unit critical care outcomes inflammatory immune system
assessment of the effects of short and long term use of cpap

Conditions: Asthma

Summary: we hypothesize that the nocturnal use of continuous positive airway pressure in adults and children with asthma will decrease airway reactivity.

deep inspirations have been shown to decrease the sensitivity of airways to narrowing (airway reactivity) after inhalation of agents that induce constriction of the bronchi in healthy adults. this response is absent in adult asthmatics; however, there is data demonstrating that use of continuous positive airway pressure (cpap) for short periods of time may decrease airway reactivity in adult asthmatics. this suggests that although deep inspirations may not result in decreased airway reactivity, sustained lung inflation may lead to changes in asthmatic airway smooth muscle structure that lead to a decrease in airway reactivity. the purpose of our study is to determine whether short and long term use of cpap in children and adults leads to decreased airway reactivity. if airway reactivity is decreased with cpap, this may provide a novel therapeutic strategy for patients with asthma.

Eligibility criteria:
inclusion criteria: inclusion criteria for children 8-18 * children 8-18 years of age scheduled to start cpap for obstructive sleep apnea. * subjects can have clinically stable asthma, with no plans by their physician to change asthma therapy over the next month inclusion criteria adults 18-60 * adults 18-60 years of age, seen in adult pulmonary clinic for sleep related problems who may require treatment with nocturnal continuous positive pressure (cpap), which will be determined by polysomnography(psg) will be approached to participate in the study. exclusion criteria: exclusions for children category age 8-18 include: 1. cyanotic congenital heart disease. 2. history of acute respiratory symptoms for 3 weeks prior to testing. 3. inability to perform pulmonary function testing adequately. 4. escalation in asthma medication at time of recruitment. 5. sao2 \<93% while awake and breathing room air 6. baseline fev1 \<75% predicted exclusions for adults 18-60 include: 1. gastro-esophageal reflux requiring medical management. 2. chronic obstructive pulmonary disease. 3. use of supplemental oxygen. 4. ischemic heart disease or hypertension requiring treatment with medications other than diuretics. 5. use of systemic corticosteroid therapy during the past 6 months. 6. acute respiratory illness in the previous 8 weeks. exclusions/inclusion criteria for adults with asthma include: 1. juniper score \<1.5 2. baseline fev1 \> or equal to 70% 3. non-smoking for 6 months 4. less than 10 pack year smoking history 5. no change in asthma medications for the last 2 months 6. negative pregnancy test 7. subject cannot have sleep apnea

Keywords: asthma sleep apnea
comparison between excisional hemorrhoidectomy and haemorrhoidal dearterialisation with anopexy

Conditions: Third Degree Hemorrhoids

Summary: aim of the study is to compare short term results of 2 surgical treatment for grade 3 hemorrhoidal disease, namely: pain and postoperative morbidity,complications and effectiveness within 30 days, re-starting daily and working activity, patients' satisfaction

excisional haemorrhoidectomy is burdened by severe postoperative pain. for this reason less painful treatments have been developed, such as doppler-guided haemorrhoidal artery ligation and stapled anopexy. both techniques seem to be safe, causing little postoperative pain. a combination of the two techniques could possibly treat both bleeding and prolapse with minimal discomfort

Eligibility criteria:
inclusion criteria: * patients aged 18-80, candidate to surgery for 3rd degree hemorrhoids exclusion criteria: * previous anal surgery or pelvic radiotherapy * fecal incontinence or obstructed defecation * ibd, ibs

Keywords: hemorrhoidectomy, haemorrhoidal dearterialisation, anopexy
impact of a strategy based on bacterial dna detection to optimize antibiotics in patients with hospital-acquired pneumonia

Conditions: Pneumonia, Ventilator-Associated; Pneumonia, Bacterial

Summary: vapero is a randomized, unblinded, controlled study to measure the impact of a strategy based on the unyvero® multiplex pcr test on the adjustment of antimicrobial therapy in patients suspected with ventilator-associated or hospital-acquired pneumonia (vap/hap) requiring mechanical ventilation. the gold-standard microbiological diagnostic method for pneumonia in the icu is still culture-based identification and antimicrobial susceptibility testing (ast) despite being more than a hundred years old, with results turnaround time spanning over several days, exposing patients to potentially inappropriate broad-spectrum antimicrobial therapy. the investigators aim to measure the impact of the unyvero® testing strategy to improve the percentage of patients with vap or hap receiving early targeted antimicrobial therapy compared to standard care.


Eligibility criteria:
inclusion criteria: * adult patients hospitalized in the icu * suspected with vap or hap requiring mv exclusion criteria: * severe immunodeficiency * moribund patients (saps ii \> 90)

Keywords: ventilator-associated pneumonia hospital-acquired pneumonia antimicrobial therapy ventilator-associated pneumonia hospital-acquired pneumonia antimicrobial therapy polymerase chain reaction antibiotics stewardship polymerase chain reaction antibiotics stewardship
non-integrated costs increase effectiveness of incentives

Conditions: Control - No Incentive for Flu Vaccine; Direct Incentive; Indirect Incentive

Summary: the investigators will test the hypothesis that the control (no incentive) condition will have the lowest vaccination rate, the main task condition will have a significantly higher vaccination rate while the indirect condition will have the highest vaccination rate. participants will be randomly assigned to one of the three message conditions and their vaccination records obtained from the university occupational health department.

the investigators will send e-mails to a complete mailing list of faculty and staff at a university. each recipient will be randomly assigned to one of three conditions: control, main task incentive or indirect incentive. our main dependent variable will be whether or not participants decide to get vaccinated. the investigators will obtain their actual vaccination records from the university occupational health department. within the e-mail message, participants will indicate whether or not they intend to get vaccinated. intention serves as an indirect dependent outcome. upon clicking to indicate their intention, participants are redirected to a page which gives further instructions on how to proceed. participants who vaccinate will be asked to complete a brief follow-up questionnaire to evaluate their experience with vaccination and (for those offered and incentive) to provide contact information to receive their payment.

Eligibility criteria:
inclusion criteria: * must be faculty or staff at rutgers university. exclusion criteria: -

Keywords: incentives field study vaccination
effectiveness of conventional therapy plus pulsed-radiofrequency for herniated nucleus pulposus

Conditions: Herniated Nucleus Pulposus; Pain

Summary: the purpose of this research was to study whether the additional application of a certain medical intervention making use of radiofrequencies (pulsed-radiofrequency) would reduce pain in patients with herniated disk.

pain is an uncomfortable sensory and emotional experience that can affect quality of life. low back pain (lbp) is one of the most common causes of pain, with herniated nucleus pulposus (hnp) being a common etiology. pulsed radiofrequency (prf) is a relatively novel technique that has shown promising results in many applications, including spinal pain conditions. this quasi-experimental study aimed to compare pain levels between patients who underwent conventional therapy (ct) alone and ct plus prf as management in patients with hnp. pain severity was measured in the numeric rating scale before and 1 month after treatment.

Eligibility criteria:
inclusion criteria: * having an established diagnosis of hnp * complaint present for at least the pas 3 months * experiencing pain intensity of 4 or greater on the numeric rating scale * capable of giving informed consent exclusion criteria: * pregnant patients * presence of infection at the site of pulsed radiofrequency * hnp with red flags.